LinkMed

The LinkMed portfolio consists of a number of life science companies, several of which are nearing the commercialization phase, while others are already selling their products or services. Between them, these companies account for more than 50 different projects in a wide range of therapeutic areas – from HIV and cancer to eye disease and allergies.

COMPANIES IN SEVERAL SECTORS
LinkMed has created a portfolio of twelve companies, four in drug development and biotechnology and eight in diagnostics and medical technology

MANY COMPANIES, LOWER RISKS
By investing in several companies, we spread risks and reduce our exposure to the development in individual projects. Our goal is to continually develop and manage between 15 and 20 portfolio companies. Therefore, we plan to invest in several new companies in the coming years.

For better, safer and ethical allergen tests

Operations: Biovator develops tests that predict if chemical sub-stances may cause allergies. The technology has the potential to substantially reduce the need for animal testing, since it is less expensive, quicker to use and provides more reliable results. The tests are developed for use in the pharmaceutical, cosmetic and chemical industries.

Sektor: Diagnostics and medical technology

Therapeutic area: Allergic reactions

CEO: Stan Mikulowski

Chairman: Ingemar Lagerlöf

Venture manager: Stan Mikulowski

Ownership stake: 57.2%

Address: Biovator AB
Box 7710
Drottninggatan 33
SE-103 95 Stockholm

www.biovator.com

Back